Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | EBP | Q15125 | 2/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6140314 | 0.86 | DRD2 (0.47) | DRD2ATMABCB1ABCG2STAT3 | |
| SCHEMBL6049294 | 0.84 | DRD2 (0.43) | DRD2ATMABCB1ABCG2STAT3 | |
| SCHEMBL6139009 | 0.84 | TRPV1 (0.43) | DRD2SIGMAR1EBPTMEM97 | |
| SCHEMBL6049410 | 0.81 | ADRB2 (0.53) | DRD2KDM4ESTAT3POLBGAA | |
| SCHEMBL24541757 | 0.80 | ATM (0.66) | DRD2KDM4EATMPOLBCYP19A1 | |
| SCHEMBL6049249 | 0.80 | PLAAT3 (0.42) | DRD2POLBGAASIGMAR1EBP | |
| SCHEMBL1966403 | 0.78 | KDM4E (0.54) | KDM4EATMABCB1ABCG2STAT3 | |
| SCHEMBL6663695 | 0.77 | DRD2 (0.53) | DRD2KDM4EATMPOLBGAA | |
| SCHEMBL6049246 | 0.76 | STAT3 (0.57) | DRD2KDM4EATMSTAT3POLB | |
| SCHEMBL9468333 | 0.76 | ATM (0.66) | KDM4EATMABCB1STAT3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264480-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2006-11-23 | — | — | US | disclosed |
| US-20030203944-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264480-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TRPV5 | DRD2 1369/4885KDM4E 4307/4885ATM 3950/4885 |
| US-20030203944-A1 | Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TRPV5 | DRD2 1369/4885KDM4E 4307/4885ATM 3950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.